Durvalumab with gemcitabine and cisplatin [DUR8]

For neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with durvalumab (in combination with gemcitabine and cisplatin chemotherapy) will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically determined diagnosis of resectable muscle-invasive bladder cancer, and the intent is to treat the patient with a radical cystectomy following systemic neo-adjuvant treatment.
3. The patient has disease which is staged as below

• T2-T4a and
• N0 or N1 and
• M0

4. The patient has not received any prior chemotherapy or immunotherapy for the treatment of muscle-invasive bladder cancer.
5. The patient has had no prior treatment with anti–CTLA‑4, anti–PD‑1, anti–PD‑L1, or anti–PD‑L2 antibodies for a bladder cancer indication.
6. In the neo-adjuvant phase, durvalumab will be given alongside gemcitabine and cisplatin chemotherapy, at a dose of 1,500mg every THREE weeks, for FOUR cycles prior to surgery.
7. Treatment with adjuvant durvalumab monotherapy will be given at a dose of 1,500mg every FOUR weeks.
8. Treatment with adjuvant durvalumab monotherapy will continue until disease progression or unacceptable toxicity or withdrawal of patient consent or for a maximum of EIGHT doses post-surgery, whichever occurs first.
9. The patient has a current ECOG performance status of 0 or 1.
10. When a treatment break of more than 12 weeks beyond the expected 3-, or 4-weekly cycle length is needed, I will complete a treatment break approval form to restart treatment. This must be approved before durvalumab is re-commenced.
11. Durvalumab will be otherwise used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 10 February 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.386 of the CDF list, downloaded from NHS England’s website on 12 February 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.